Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms

Brain

Volumn 136, Issue 8, 2013, Pages 2369-2378

  Perier, Celine ^a   Bender, Andreas ^b   García Arumí, Elena ^c   Melià, Ma Jesus ^c   Bové, Jordi ^a   Laub, Christoph ^b   Klopstock, Thomas ^b   Elstner, Matthias ^b   Mounsey, Ross B ^d   Teismann, Peter ^d   Prolla, Tomas ^e   Andreu, Antoni L ^c   Vila, Miquel ^a,f,g,h  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Mitochondria; MtDNA deletions; Neurodegeneration; Parkinson disease

Indexed keywords

CYTOCHROME C OXIDASE; DNA POLYMERASE; DOPAMINE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; HISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL RESPIRATION; MORPHOLOGY; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84880954005     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt196     Document Type: Article

References (25)

1. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-7.
2. Davidzon G, Greene P, Mancuso M, Klos KJ, Ahlskoq JE, Hirano M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 2006; 59: 859-62.
3. Ekstrand MI, Terzioglu M, Galter D. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007; 104: 1325-30.
4. Elstner M, Muller SK, Leidolt L, Laub C, Krieg L, Schlaudraff F, et al. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol Brain 2011; 4: 43.
5. Frezza C, Cipolat S, Martins DBO, Micaroni M, Beznoussenko GV, Rudka T, et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 2006; 126: 177-89.
6. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006; 38: 518-20.
7. Krishnan KJ, Bender A, Taylor RW, Turnbull DM. A multiplex real-time PCR method to detect and quantify mitochondrial DNA deletions in individual cells. Anal Biochem 2007; 370: 127-9.
8. Kubota M, Kasahara T, Nakamura T, Ishiwata M, Miyauchi T, Kato T. Abnormal Ca2 + dynamics in transgenic mice with neuron-specific mitochondrial DNA defects. J Neurosci 2006; 26: 12314-24.
9. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309: 481-4.
10. Liberatore G, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 1999; 5: 1403-9.
11. Lin MT, Cantuti-Castelvetri I, Zheng K, Jackson KE, Tan YB, Arzberger T, et al. Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol 2012; 71: 850-4.
12. Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004; 364: 875-82.
13. Mott JL, Zhang D, Stevens M, Chang S, Denniger G, Zassenhaus HP. Oxidative stress is not an obligate mediator of disease provoked by mitochondrial DNA mutations. Mutat Res 2001; 474: 35-45.
14. Perier C, Bove J, Dehay B, Jackson-Lewis V, Rabinovitch PS, Przedborski S, et al. Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann Neurol 2010; 68: 184-92.
15. Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V, et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA 2005; 102: 19126-31.
16. Pickrell AM, Pinto M, Hida A, Moraes CT. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 2011; 31: 17649-58.
17. Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004; 36: 375-9.
18. Ramonet D, Perier C, Recasens A, Dehay B, Bové J, Costa V, et al. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ 2013; 20: 77-85.
19. Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, et al. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 2012; 135: 3336-47.
20. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 2003; 112: 892-901.
21. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429: 417-23.
22. Vermulst M, Wanagat J, Kujoth GC, Beilas JH, Rabinovitch PS, Prolla TA, et al. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 2008; 40: 392-4.
23. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39: 359-407.
24. Zhang D, Mott JL, Chang SW, Denniger G, Feng Z, Zassenhaus HP. Construction of transgenic mice with tissue-specific acceleration of mitochondrial DNA mutagenesis. Genomics 2000; 69: 151-61.
25. Zhang D, Mott JL, Farrar P, Ryerse JS, Chang SW, Stevens M, et al. Mitochondrial DNA mutations activate the mitochondrial apoptotic pathway and cause dilated cardiomyopathy. Cardiovasc Res 2003; 57: 147-57.